Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
2.170
-0.050 (-2.25%)
At close: Aug 29, 2025, 4:00 PM
2.130
-0.040 (-1.84%)
After-hours: Aug 29, 2025, 4:12 PM EDT
Allurion Technologies Revenue
Allurion Technologies had revenue of $3.38M in the quarter ending June 30, 2025, a decrease of -71.28%. This brings the company's revenue in the last twelve months to $19.92M, down -58.15% year-over-year. In the year 2024, Allurion Technologies had annual revenue of $32.11M, down -39.94%.
Revenue (ttm)
$19.92M
Revenue Growth
-58.15%
P/S Ratio
0.48
Revenue / Employee
$145,380
Employees
137
Market Cap
16.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 32.11M | -21.36M | -39.94% |
Dec 31, 2023 | 53.47M | -10.74M | -16.73% |
Dec 31, 2022 | 64.21M | 25.97M | 67.91% |
Dec 31, 2021 | 38.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALUR News
- 16 days ago - Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 22 days ago - Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025 - Business Wire
- 24 days ago - Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry - Business Wire
- 5 weeks ago - Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program - Business Wire
- 7 weeks ago - Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss - Business Wire
- 7 weeks ago - Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints - Business Wire
- 2 months ago - Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS - Business Wire